Effectiveness of the WearME System for COPD Severity and Respiratory Function
Part of paid clinical trials in Baltimore, Maryland.
- Sponsor
- LASARRUS Clinic and Research Center
- Study ID
- NCT06751537
- Status
- Recruiting
Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
Eligibility Criteria
- Sex
- ALL
- Age
- 21 Years - 100 Years
- Healthy Volunteers
- Not accepted
Study Details
This observational study evaluates the effectiveness of the WearME system in monitoring COPD severity and respiratory function by comparing its measurements to standard spirometry, capnography, and other clinical assessments in 128 COPD participants.
Key Dates
- Start date
- May 29, 2025
- Status verified
- Sep 2025
- Primary completion
- Jan 31, 2026
- Completion
- Feb 28, 2026
Study Design
- Enrollment
- 128 participants (estimated)
Arms
- Arm: COPD ParticipantsParticipants are wearing the WearME device and undergoing reference testing
Primary Outcome Measure
Agreement between WearME-Pro system and gold standard devices for FEV1 measurements, stratified by COPD severity. [ Time Frame: Within 6 months of study start. ]
Central Contacts
- Lloyd E Emokpae, PhD.301-388-5453
- Roland N Emokpae, MD301-388-8067
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Johns Hopkins | Baltimore | Maryland | 21224 | Edward Chen, MD (SUB_INVESTIGATOR) |
| TidalHealth | Salisbury | Maryland | 21801 | Robert T Chasse, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Baltimore, MD
By research site
Related Studies
- Multi-Center Clean Air Randomized Controlled Trial in COPDPHASE3 · Recruiting · JHSPH Center for Clinical Trials · Birmingham, Alabama
- A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)PHASE3 · Recruiting · AstraZeneca · Cullman, Alabama
- A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)PHASE3 · Recruiting · AstraZeneca · Foley, Alabama
- Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPDPHASE2 · Recruiting · Johns Hopkins University · Birmingham, Alabama